Recent Updates
Recently added Catalysts

JNJ-10450232 / Not yet marketed

Phase 2

Pain | Small molecule | Pain |Johnson & Johnson|Last Updated: Feb 3, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment269
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02209181A Dental Pain Study to Test the Effectiveness of a New Pain Reliever MedicinePHASE2 COMPLETED 269Aug 1, 2014Apr 1, 2015Feb 3, 20171 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Analgesic Efficacy From 0 to 6 Hours After the Dose Using the Time-weighted Sum of Pain Intensity Difference (SPID 0-6)
6 Hours

Time-weighted sum of pain intensity difference by first multiplying each pain intensity difference (PID) score by the time from the previous time point, and adding them together for each scheduled time point within 0-6 hours. Time points included 15 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours. The minimum SPID 0-6 was -30 and the maximum SPID 0-6 was 60, where higher is better. Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain).

Secondary Endpoints
Pain Intensity Difference From Baseline (PID) Scores at 15 Minutes Post Dose
Baseline to 15 minutes post dose
Pain Intensity Difference From Baseline (PID) Scores at 30 Minutes Post Dose
Baseline to 30 minutes post dose
Pain Intensity Difference From Baseline (PID) Scores at 45 Minutes Post Dose
Baseline to 45 minutes post dose
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
JNJ-10450232 250 mgEXPERIMENTAL -
JNJ-10450232 1000 mgEXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -
Acetaminophen 1000 mgACTIVE_COMPARATOR -
Interventions
NameTypeDescription
JNJ-10450232 / Not yet marketedDRUGSubjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
acetaminophen / TylenolDRUGSubjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexMALE
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Subjects aged 18-45 years * At least moderate dental pain assessed by a categorical scale pain intensity scale and a score of at least 5 on the 11-point (0-10) pain intensity numerical rating scale (PI-NRS) following surgical removal of three third-molars Exclusion Criteria: ...

Countries:United States
Unlock Eligibility Criteria